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This manuscript presents the concerns around the increasingly common problem of not having readily available or
useful “gold standard” measurements. This issue is particularly important in critical care where many measurements
used in decision making are surrogates of what we would truly wish to use. However, the question is broad,
important and applicable in many other areas.
In particular, a gold standard measurement often exists, but is not clinically (or ethically in some cases) feasible. The
question is how does one even begin to develop new measurements or surrogates if one has no gold standard to
compare with?
We raise this issue concisely with a specific example from mechanical ventilation, a core bread and butter therapy in
critical care that is also a leading cause of length of stay and cost of care. Our proposed solution centers around a
hierarchical validation approach that we believe would ameliorate ethics issues around radiation exposure that make
current gold standard measures clinically infeasible, and thus provide a pathway to create a (new) gold standard.
Keywords: Gold standard, Mechanical ventilation, Research methodology, Validation, Clinical trials, Animal trialsThe gold standard
Medicine is dominated by measurements. Behind virtually
every decision lurks one or more measurements of one or
more physiological or biochemical parameters. Although
it is sometimes less directly acknowledged, there is the
obvious significant impact of the quality of the measure-
ment on the ability to deliver the desired quality of care.
Thus, for most measurements in medicine, there exists
one or more “gold standards”. While there is debate over
the definition [1], “gold standard” here simply represents
the best available measurement of a parameter, even if it
is not the most cost effective or clinically feasible. These
gold standards are the metrics to which any new meas-
urement is compared, as well as the means by which
potential variability in study outcomes can be assessed.
Incorporating evidence-based medicine into current
clinical practice is a main avenue for optimizing care [2].
However, this goal has proven very difficult in critical
care medicine, where there are numerous examples of
clinical trials yielding conflicting results or failing to de-
liver clear results. It bears repeating that measurements
are at the heart of the intervention and outcome assess-
ment in these clinical trials. The practice of critical care,* Correspondence: tdesaive@ulg.ac.be
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metrics that are surrogates of pathophysiological pro-
cesses. Diagnostics in critical care are not primarily la-
boratory based, as they are in oncology or hematology
for example. Thus, one can test for cell markers in
types of lymphoma, but there are no gold standard
diagnostics to quantify pathophysiological processes
seen in acute respiratory distress syndrome (ARDS) and
septic shock. Yet, managing these conditions and other
pathophysiological derangements are the ‘bread and
butter’ of critical care.
Mechanical ventilation (MV) in ARDS is one area for
which there is no well-accepted approach to care, in
particular, positive end expiratory pressure (PEEP) selec-
tion, with several conflicting randomised trial results [3].
The main goals of MV are to support patient breathing
and, where possible, select a PEEP that safely maximises
recruitment. Thus, while clinical outcome variables, such
as mortality or length of MV, can be linked to a given
approach or method, there is no guarantee that the inter-
vention being tested achieved the recruitment desired [4].
Fortunately, there is a relatively well-accepted gold
standard measurement of recruitment, the Computed
Tomography or CT scan, that is currently the most
accepted, if not fully proven, metric for titrating care
[5]. Certainly, one or more CT slices of the lung cantd. This is an Open Access article distributed under the terms of the Creative
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Figure 1 A simple 3-phase validation pathway.
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providing clear, direct and effective measurement of
the immediate clinical outcome and impact of an inter-
vention. It has been used in animal studies [7,8] and some
human studies [6] to assess recruitment, although it is not
effective for repeated dynamic assessments.
In particular, there is increasing opposition to using, or
overusing, radiation medical imaging, and CT in particu-
lar, even in research studies [9,10]. Equally, CT has never
been very practical, nor cost effective, in clinical practice
for assessing recruitment. Just moving the patient and
having to ventilate using a longer breathing circuit can
significantly impact pulmonary mechanics and patient
condition. Finally, it is not only impractical to use CT
to make frequent adjustments of PEEP (up to 4 times
daily), but it would also expose patients to unacceptably
high doses of radiation.
Thus, the field is left without any gold standard that
can effectively or ethically be used in care or research.
This latter use is critical, because without a high quality
gold standard that is also clinically feasible, it is not possible
to safely or effectively translate animal studies or similar
results into human studies and improved outcomes. As a
result, emerging non-invasive approaches, such as elec-
trical impedance tomography (EIT) [11] and model-based
methods [12], cannot even be assessed to determine their
efficacy in humans. This failure leaves these modalities
stranded without a means of validation in human subjects.
More specifically, when there is no gold standard direct
measurement, there is no way to prove its replacement or
surrogate has equal or effective clinical value.
A path forward
What would be useful is a validation roadmap by which
new methods could be assessed safely and ethically.
Figure 1 shows a 3-phase validation approach with the
narrowing pyramid indicating that potential for fewer
methods to pass each stage. The end goal is validation
on critically ill cohorts, but only subsequent to proof
that any new method can:
 Accurately capture recruitment and recruited
volume in the heterogeneous ARDS lung.
 Work effectively in humans.
The specific phases in Figure 1 are rationalized:
1. Animal Trials: allow a heterogeneous ARDS lung to
be induced and for a method to be tested over the
evolution of the disease state. Several CT slices can
be taken at each step without concern over radiation
dose. Several slices enable any method to accurately
quantify error and error relative to the variability
across the CT slices.2. Healthy Human Trials: allow any method to show it
works in humans. Given recent evidence that
modest recruitment can be obtained in the healthy
human lung with small added pressure, this
validation should be enough to show ability to work
with human anatomy. In these trials, only a single
CT slice might be taken to minimise radiation.
Healthy humans are chosen for this level because
they can tolerate a small radiation dose with the
minimum possible risk.
3. Critically Ill Trials: the final validation on MV
patients, using only a single CT slice as required as
final validation of any concept that passes the first
two phases.
Thus, using this approach, there are no trials on critic-
ally ill patients and no significant added risk until a new
method is proven in animals (no added human risk) and
healthy humans (no significant added human risk).Some final thoughts
So, where does this situation leave us? Perhaps the gold
standard does not exist. Perhaps, we should abandon the
‘gold standard’, as governments did in the 1930’s, for a
more adaptive method that can provide real-time metrics
that could be ultimately compared in large well designed
randomised trials. Or possibly, we should create a consen-
sus or agreed pathway to creating a true gold standard
to enable better randomised trials and thus better care.
Otherwise, these issues leave the field without mea-
surements that are critical for providing and, especially,
improving care. It is a general problem, what do you do
when the value of (your) gold (standard) is zero?Ethics committee approval
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